BioCardia

125 Shoreway Road, Suite B

San Carlos

California

94070

United States

(650) 226-0120

(650) 631-3731

[email protected]

Related Content

Partnership targets heart failure, the leading cause of death and a condition with limited treatment options

News | Heart Failure

BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership

March 15, 2024 — BioCardia, Inc. , a biotechnology company focused on advancing late-stage cell therapy interventions ...

March 15, 2024

News | Heart Failure

BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership

March 15, 2024 — BioCardia, Inc., a biotechnology company focused on advancing late-stage cell therapy interventions for ...

March 15, 2024

BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced Centers for Medicare & Medicaid Services (CMS) approval for reimbursement coverage of the confirmatory Phase III clinical trial of CardiAMP autologous cell therapy for the treatment of patients with ischemic heart failure.

News | Heart Failure

BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

March 13, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

March 13, 2024

CardiAMP cell therapy-treated patients had 37% relative risk reduction in heart death equivalent (death, heart transplant, left ventricular assist device implantation) and 9% relative risk reduction in non-fatal major adverse cardiac and cerebrovascular events

News | FDA

Biocardia Reports Positive Interim Results from Phase III Cardiamp Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure

March 7, 2024 — BioCardia, Inc. , a biotechnology company focused on advancing late-stage cell therapy interventions for ...

March 07, 2024

BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announced that the first patient was enrolled and treated in its CardiALLO Allogeneic Mesenchymal Cell Therapy Phase I/II trial

News | Cardiovascular Clinical Studies

BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction

December 19, 2023 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

December 19, 2023

Japan’s PMDA asked for further details on a number of elements included in BioCardia’s CardiAMP preclinical and clinical packages in order to gain approval.

News | Heart Failure

BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval

November 30, 2023 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

November 30, 2023

BioCardia announces that the Food and Drug Administration (FDA) has approved its proposed CardiAMP Heart Failure II study protocol

News | FDA

BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure

November 17, 2023 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

November 17, 2023

Novel platform for structural heart interventions now in human use, with ability to improve patient recovery and reduce anesthesia and hospital stays

News | Cardiovascular Clinical Studies

BioCardia Announces Completion of Enrollment in Phase III CardiAMP HF Trial and Plans for CardiAMP HF Trial II

October 12, 2023 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

October 12, 2023

the Company is exploring development of a new Phase III clinical trial protocol

News | Heart Failure

BioCardia Announces Clarification and Next Steps on its Autologous CardiAMP Cell Therapy Programs

September 8, 2023 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

September 08, 2023

BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, announced that the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for the ongoing Phase III pivotal CardiAMP Cell Therapy Heart Failure Trial

News | Cardiovascular Clinical Studies

BioCardia Announces DSMB Recommendation to Pause New Enrollment in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial While Additional Blinded Data is Collected

July 24, 2023 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

July 24, 2023